| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Vaccines | 32 | 2021 | 1033 | 7.740 |
Why?
|
| Mucin-1 | 21 | 2017 | 545 | 4.570 |
Why?
|
| Dendritic Cells | 40 | 2021 | 2779 | 4.230 |
Why?
|
| Multiple Myeloma | 43 | 2021 | 4844 | 3.830 |
Why?
|
| Hematologic Neoplasms | 14 | 2021 | 1556 | 2.420 |
Why?
|
| Immunotherapy | 21 | 2020 | 3793 | 2.420 |
Why?
|
| Leukemia, Myeloid, Acute | 15 | 2022 | 3027 | 1.900 |
Why?
|
| Immunotherapy, Active | 3 | 2018 | 77 | 1.710 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 29 | 2022 | 4883 | 1.550 |
Why?
|
| Immunotherapy, Adoptive | 11 | 2021 | 869 | 1.510 |
Why?
|
| Azacitidine | 3 | 2019 | 291 | 1.310 |
Why?
|
| Cell Fusion | 12 | 2012 | 321 | 1.100 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 193 | 1.090 |
Why?
|
| Vaccination | 11 | 2022 | 2487 | 1.030 |
Why?
|
| Antigens, Neoplasm | 8 | 2021 | 2176 | 0.950 |
Why?
|
| T-Lymphocytes | 19 | 2021 | 10329 | 0.930 |
Why?
|
| Thalidomide | 5 | 2017 | 907 | 0.850 |
Why?
|
| Graft vs Host Disease | 14 | 2022 | 2708 | 0.850 |
Why?
|
| Tumor Microenvironment | 7 | 2019 | 2503 | 0.750 |
Why?
|
| Immunomodulation | 4 | 2018 | 547 | 0.740 |
Why?
|
| Stem Cell Transplantation | 9 | 2018 | 1660 | 0.720 |
Why?
|
| Transplantation Conditioning | 7 | 2020 | 1514 | 0.700 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2019 | 11115 | 0.700 |
Why?
|
| T-Lymphocytes, Regulatory | 10 | 2017 | 2938 | 0.700 |
Why?
|
| Cell Proliferation | 17 | 2020 | 10990 | 0.690 |
Why?
|
| Transplantation, Homologous | 11 | 2018 | 4917 | 0.660 |
Why?
|
| Interleukin-12 | 4 | 2008 | 601 | 0.650 |
Why?
|
| Remission Induction | 9 | 2017 | 2387 | 0.650 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 665 | 0.620 |
Why?
|
| Lymphocyte Activation | 18 | 2018 | 5989 | 0.620 |
Why?
|
| Antibodies, Monoclonal | 13 | 2016 | 9863 | 0.620 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 7 | 2022 | 916 | 0.610 |
Why?
|
| Melphalan | 5 | 2019 | 364 | 0.590 |
Why?
|
| Peptides | 6 | 2017 | 4537 | 0.570 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2019 | 324 | 0.550 |
Why?
|
| Lymphoma, B-Cell | 4 | 2021 | 900 | 0.540 |
Why?
|
| Antibodies, Neoplasm | 1 | 2015 | 365 | 0.530 |
Why?
|
| Transplantation, Autologous | 12 | 2013 | 2072 | 0.530 |
Why?
|
| Immune Tolerance | 4 | 2018 | 2355 | 0.530 |
Why?
|
| Immunity, Cellular | 5 | 2019 | 1734 | 0.520 |
Why?
|
| Cell Communication | 4 | 2017 | 1658 | 0.510 |
Why?
|
| Molecular Targeted Therapy | 5 | 2018 | 2884 | 0.470 |
Why?
|
| Dexamethasone | 4 | 2019 | 1904 | 0.470 |
Why?
|
| Lymphocyte Transfusion | 2 | 2014 | 247 | 0.470 |
Why?
|
| Coculture Techniques | 7 | 2017 | 1393 | 0.460 |
Why?
|
| Recurrence | 11 | 2020 | 8198 | 0.460 |
Why?
|
| Antigen Presentation | 7 | 2012 | 1364 | 0.450 |
Why?
|
| Humans | 142 | 2022 | 686663 | 0.450 |
Why?
|
| MicroRNAs | 5 | 2020 | 3587 | 0.440 |
Why?
|
| Apoptosis | 11 | 2020 | 10261 | 0.440 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 378 | 0.430 |
Why?
|
| Stromal Cells | 1 | 2017 | 1385 | 0.430 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2019 | 4115 | 0.430 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2015 | 1140 | 0.430 |
Why?
|
| Cell Line, Tumor | 18 | 2020 | 17251 | 0.420 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2007 | 623 | 0.420 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2012 | 1959 | 0.420 |
Why?
|
| Antigens, CD | 5 | 2016 | 4256 | 0.410 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2017 | 1626 | 0.410 |
Why?
|
| Oxidative Stress | 3 | 2017 | 3190 | 0.370 |
Why?
|
| Granzymes | 1 | 2010 | 272 | 0.370 |
Why?
|
| Reactive Oxygen Species | 6 | 2017 | 2091 | 0.360 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2020 | 1252 | 0.350 |
Why?
|
| Cytotoxicity, Immunologic | 7 | 2017 | 1577 | 0.350 |
Why?
|
| Virus Activation | 3 | 2019 | 325 | 0.350 |
Why?
|
| Antineoplastic Agents | 13 | 2017 | 13898 | 0.340 |
Why?
|
| Bone Marrow | 2 | 2020 | 2901 | 0.340 |
Why?
|
| Kidney Neoplasms | 5 | 2007 | 4017 | 0.330 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 1390 | 0.330 |
Why?
|
| Interferon-gamma | 6 | 2017 | 3263 | 0.320 |
Why?
|
| Transplantation Immunology | 3 | 2016 | 630 | 0.320 |
Why?
|
| Antigens, Differentiation | 1 | 2010 | 991 | 0.320 |
Why?
|
| Animals | 32 | 2021 | 170849 | 0.310 |
Why?
|
| Breast Neoplasms | 14 | 2017 | 19153 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2007 | 227 | 0.310 |
Why?
|
| Leukemia | 4 | 2016 | 1449 | 0.300 |
Why?
|
| Th17 Cells | 1 | 2012 | 705 | 0.300 |
Why?
|
| Immunologic Factors | 3 | 2018 | 1477 | 0.300 |
Why?
|
| Killer Cells, Natural | 6 | 2016 | 2191 | 0.300 |
Why?
|
| Neoplasms | 8 | 2016 | 19538 | 0.300 |
Why?
|
| Immunophenotyping | 10 | 2013 | 1915 | 0.290 |
Why?
|
| Flow Cytometry | 10 | 2015 | 6230 | 0.290 |
Why?
|
| Oligonucleotides | 1 | 2008 | 605 | 0.280 |
Why?
|
| Tumor Cells, Cultured | 12 | 2019 | 6835 | 0.280 |
Why?
|
| Anilides | 2 | 2017 | 416 | 0.260 |
Why?
|
| Antigens, CD34 | 5 | 2016 | 672 | 0.260 |
Why?
|
| Boronic Acids | 4 | 2014 | 1010 | 0.250 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2007 | 2911 | 0.250 |
Why?
|
| Th1-Th2 Balance | 2 | 2012 | 36 | 0.240 |
Why?
|
| Whole-Body Irradiation | 2 | 2020 | 464 | 0.240 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 1928 | 0.240 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2014 | 143 | 0.240 |
Why?
|
| Drug Synergism | 6 | 2017 | 1939 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2020 | 8895 | 0.230 |
Why?
|
| Signal Transduction | 6 | 2017 | 24351 | 0.230 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2017 | 464 | 0.230 |
Why?
|
| Pyrazines | 4 | 2014 | 1262 | 0.230 |
Why?
|
| Cryptosporidiosis | 1 | 2021 | 46 | 0.230 |
Why?
|
| Immune System | 2 | 2018 | 813 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2015 | 741 | 0.220 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 3853 | 0.210 |
Why?
|
| Hodgkin Disease | 3 | 2019 | 1428 | 0.210 |
Why?
|
| Mice | 20 | 2021 | 80803 | 0.210 |
Why?
|
| Photopheresis | 1 | 2020 | 31 | 0.210 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2021 | 82 | 0.210 |
Why?
|
| Down-Regulation | 3 | 2019 | 3226 | 0.210 |
Why?
|
| Oncogene Proteins | 2 | 2016 | 765 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2017 | 1042 | 0.210 |
Why?
|
| Mice, SCID | 3 | 2016 | 2913 | 0.200 |
Why?
|
| Cell Differentiation | 10 | 2017 | 11833 | 0.200 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 675 | 0.200 |
Why?
|
| Biomedical Research | 3 | 2010 | 3285 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 3881 | 0.200 |
Why?
|
| Mice, Inbred NOD | 2 | 2015 | 1974 | 0.190 |
Why?
|
| Vitamin D | 2 | 2012 | 3064 | 0.190 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 324 | 0.190 |
Why?
|
| Isoantigens | 2 | 2017 | 590 | 0.190 |
Why?
|
| Lymphocyte Culture Test, Mixed | 6 | 2009 | 664 | 0.190 |
Why?
|
| Cytarabine | 3 | 2019 | 683 | 0.180 |
Why?
|
| Hematopoietic Stem Cells | 6 | 2013 | 3457 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 5114 | 0.180 |
Why?
|
| Blotting, Western | 4 | 2015 | 5678 | 0.180 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 430 | 0.180 |
Why?
|
| Middle Aged | 49 | 2021 | 216468 | 0.180 |
Why?
|
| Female | 58 | 2021 | 375459 | 0.180 |
Why?
|
| Interleukin-2 | 3 | 2016 | 1981 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2020 | 1181 | 0.180 |
Why?
|
| Lymphoma | 5 | 2020 | 1863 | 0.180 |
Why?
|
| Oxidation-Reduction | 4 | 2017 | 2334 | 0.180 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 616 | 0.180 |
Why?
|
| Cross-Priming | 1 | 2017 | 78 | 0.170 |
Why?
|
| Herpesvirus 6, Human | 1 | 2018 | 96 | 0.170 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2019 | 239 | 0.170 |
Why?
|
| Vinblastine | 1 | 2019 | 527 | 0.170 |
Why?
|
| Forkhead Transcription Factors | 4 | 2017 | 1551 | 0.170 |
Why?
|
| Perforin | 1 | 2017 | 174 | 0.170 |
Why?
|
| Azepines | 1 | 2019 | 350 | 0.170 |
Why?
|
| Glutathione | 3 | 2015 | 635 | 0.170 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2018 | 267 | 0.170 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2010 | 428 | 0.160 |
Why?
|
| Receptors, CCR7 | 2 | 2008 | 115 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2017 | 5265 | 0.160 |
Why?
|
| Mitoxantrone | 3 | 2017 | 158 | 0.160 |
Why?
|
| JC Virus | 2 | 2014 | 96 | 0.160 |
Why?
|
| Galactosylceramides | 1 | 2017 | 97 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 5354 | 0.160 |
Why?
|
| Aged | 34 | 2021 | 162271 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2017 | 298 | 0.160 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1998 | 273 | 0.160 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2015 | 412 | 0.160 |
Why?
|
| HMGB1 Protein | 1 | 2017 | 136 | 0.160 |
Why?
|
| Tretinoin | 1 | 2019 | 519 | 0.150 |
Why?
|
| Adult | 43 | 2020 | 211400 | 0.150 |
Why?
|
| Male | 48 | 2021 | 352465 | 0.150 |
Why?
|
| Retroviridae | 1 | 2019 | 986 | 0.150 |
Why?
|
| Polydeoxyribonucleotides | 2 | 2010 | 120 | 0.150 |
Why?
|
| Dacarbazine | 1 | 2019 | 588 | 0.150 |
Why?
|
| Neoplasm, Residual | 2 | 2020 | 932 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2001 | 649 | 0.150 |
Why?
|
| Ribonuclease III | 1 | 2017 | 256 | 0.150 |
Why?
|
| Blood Specimen Collection | 1 | 2016 | 257 | 0.150 |
Why?
|
| Doxorubicin | 4 | 2019 | 2249 | 0.150 |
Why?
|
| Etoposide | 3 | 2017 | 632 | 0.150 |
Why?
|
| Tumor Escape | 1 | 2018 | 352 | 0.140 |
Why?
|
| Hybrid Cells | 2 | 2005 | 493 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 3 | 2017 | 2880 | 0.140 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2010 | 220 | 0.140 |
Why?
|
| Pyridines | 2 | 2017 | 2843 | 0.140 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 468 | 0.140 |
Why?
|
| Cell Survival | 5 | 2016 | 6288 | 0.140 |
Why?
|
| NADP | 1 | 2015 | 241 | 0.140 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2014 | 113 | 0.140 |
Why?
|
| Yttrium Radioisotopes | 1 | 2015 | 96 | 0.140 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 2296 | 0.140 |
Why?
|
| Response Elements | 1 | 2016 | 338 | 0.140 |
Why?
|
| Immunoblotting | 3 | 2014 | 1840 | 0.140 |
Why?
|
| Antigen-Presenting Cells | 1 | 2018 | 970 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2016 | 554 | 0.140 |
Why?
|
| Gene Silencing | 3 | 2017 | 1668 | 0.130 |
Why?
|
| Leukapheresis | 3 | 2003 | 128 | 0.130 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 311 | 0.130 |
Why?
|
| Transplantation | 1 | 2015 | 248 | 0.130 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 761 | 0.130 |
Why?
|
| Fetal Blood | 2 | 2019 | 1370 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 3006 | 0.130 |
Why?
|
| Janus Kinase 2 | 1 | 2017 | 505 | 0.130 |
Why?
|
| Necrosis | 2 | 2015 | 1664 | 0.130 |
Why?
|
| Lymphoma, T-Cell | 1 | 2016 | 319 | 0.130 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2018 | 497 | 0.130 |
Why?
|
| Fowlpox virus | 1 | 2012 | 20 | 0.130 |
Why?
|
| Interleukin-10 | 3 | 2009 | 1209 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 786 | 0.120 |
Why?
|
| PPAR delta | 1 | 2012 | 47 | 0.120 |
Why?
|
| Parathyroid Hormone | 2 | 2012 | 1841 | 0.120 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 245 | 0.120 |
Why?
|
| Arabinonucleosides | 1 | 2012 | 34 | 0.120 |
Why?
|
| Antigens, CD1 | 3 | 2008 | 485 | 0.120 |
Why?
|
| Treatment Outcome | 18 | 2018 | 60991 | 0.120 |
Why?
|
| Adenine Nucleotides | 1 | 2012 | 136 | 0.120 |
Why?
|
| Cells, Cultured | 7 | 2014 | 20620 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 1 | 2018 | 1221 | 0.120 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2003 | 276 | 0.120 |
Why?
|
| Ifosfamide | 2 | 2003 | 227 | 0.120 |
Why?
|
| STAT Transcription Factors | 1 | 2012 | 158 | 0.120 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 137 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2001 | 1437 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 968 | 0.110 |
Why?
|
| Interleukin-4 | 3 | 2014 | 1159 | 0.110 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 554 | 0.110 |
Why?
|
| Hematologic Diseases | 2 | 2012 | 484 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2021 | 2410 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2012 | 1914 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 1157 | 0.110 |
Why?
|
| Combined Modality Therapy | 6 | 2016 | 9114 | 0.100 |
Why?
|
| Lymphocyte Depletion | 2 | 2006 | 652 | 0.100 |
Why?
|
| Cytokines | 3 | 2017 | 7147 | 0.100 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2010 | 76 | 0.100 |
Why?
|
| Viral Proteins | 1 | 2018 | 1996 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 1889 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2015 | 13469 | 0.100 |
Why?
|
| Mitogens | 1 | 2010 | 266 | 0.100 |
Why?
|
| Pyrimidines | 2 | 2019 | 2909 | 0.100 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 241 | 0.100 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2011 | 433 | 0.100 |
Why?
|
| Multiple Organ Failure | 2 | 2010 | 372 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 2902 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 1799 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2017 | 1674 | 0.090 |
Why?
|
| Sirolimus | 1 | 2017 | 1605 | 0.090 |
Why?
|
| Radiation Injuries | 1 | 2017 | 1274 | 0.090 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 994 | 0.090 |
Why?
|
| Survival Analysis | 7 | 2019 | 10766 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 3 | 2017 | 945 | 0.090 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 321 | 0.090 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2005 | 453 | 0.090 |
Why?
|
| Cell Separation | 3 | 2016 | 1874 | 0.090 |
Why?
|
| DNA Methylation | 2 | 2019 | 3987 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 831 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 23439 | 0.090 |
Why?
|
| Cell Division | 3 | 2012 | 4906 | 0.080 |
Why?
|
| Authorship | 1 | 2010 | 257 | 0.080 |
Why?
|
| Isocoumarins | 1 | 2006 | 16 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2017 | 4441 | 0.080 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 1476 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 2628 | 0.080 |
Why?
|
| Antimitotic Agents | 1 | 2006 | 30 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2012 | 4355 | 0.080 |
Why?
|
| Survival Rate | 8 | 2015 | 13606 | 0.080 |
Why?
|
| Clone Cells | 1 | 2010 | 1776 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 18495 | 0.080 |
Why?
|
| Filgrastim | 2 | 2007 | 142 | 0.080 |
Why?
|
| Fibrinolytic Agents | 2 | 2010 | 2132 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 2912 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 1307 | 0.080 |
Why?
|
| Disease-Free Survival | 7 | 2015 | 7195 | 0.080 |
Why?
|
| Cell Polarity | 1 | 2010 | 681 | 0.080 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2004 | 44 | 0.070 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 889 | 0.070 |
Why?
|
| Interleukin-7 | 1 | 2005 | 128 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 6009 | 0.070 |
Why?
|
| Lymphocyte Count | 3 | 2016 | 804 | 0.070 |
Why?
|
| Tissue Donors | 3 | 2018 | 2035 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 4208 | 0.070 |
Why?
|
| Fatty Acids | 1 | 2012 | 1701 | 0.070 |
Why?
|
| Conflict of Interest | 1 | 2010 | 604 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2009 | 647 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2014 | 3105 | 0.070 |
Why?
|
| Bone Marrow Cells | 3 | 2004 | 2698 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 9337 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 5252 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2013 | 8610 | 0.060 |
Why?
|
| Disclosure | 1 | 2010 | 766 | 0.060 |
Why?
|
| Antibody Formation | 2 | 2005 | 1416 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2018 | 3271 | 0.060 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 59331 | 0.060 |
Why?
|
| Young Adult | 11 | 2019 | 56052 | 0.060 |
Why?
|
| Gene Expression | 1 | 2017 | 8182 | 0.060 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 1416 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2015 | 21684 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2008 | 1345 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 8070 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 6970 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2008 | 1065 | 0.060 |
Why?
|
| Glucocorticoids | 4 | 2018 | 2100 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 3053 | 0.060 |
Why?
|
| Sterilization | 1 | 2003 | 129 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2012 | 3628 | 0.060 |
Why?
|
| Drug Industry | 1 | 2010 | 904 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2005 | 675 | 0.060 |
Why?
|
| Drug Administration Schedule | 5 | 2013 | 5182 | 0.050 |
Why?
|
| Pentostatin | 1 | 2020 | 27 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2007 | 1052 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 8130 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2000 | 116 | 0.050 |
Why?
|
| Phytohemagglutinins | 1 | 2000 | 219 | 0.050 |
Why?
|
| K562 Cells | 3 | 2010 | 662 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2005 | 418 | 0.050 |
Why?
|
| Mitosis | 1 | 2006 | 1276 | 0.050 |
Why?
|
| Idarubicin | 1 | 2019 | 62 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2012 | 11910 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2011 | 2099 | 0.050 |
Why?
|
| Antibodies | 1 | 2008 | 2421 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 4716 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 4 | 2013 | 6786 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 273 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2002 | 641 | 0.050 |
Why?
|
| Chronic Disease | 4 | 2018 | 8882 | 0.050 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2000 | 539 | 0.050 |
Why?
|
| U937 Cells | 1 | 2019 | 282 | 0.050 |
Why?
|
| Foscarnet | 1 | 2018 | 39 | 0.050 |
Why?
|
| Salvage Therapy | 2 | 2017 | 1311 | 0.050 |
Why?
|
| Prednisone | 2 | 2018 | 1588 | 0.050 |
Why?
|
| Vidarabine | 1 | 2019 | 348 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 1472 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 2001 | 413 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2001 | 617 | 0.040 |
Why?
|
| Skin Tests | 1 | 2000 | 670 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 2772 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 10094 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 139 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 2019 | 217 | 0.040 |
Why?
|
| Contrast Media | 1 | 2011 | 5311 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 1 | 1999 | 245 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2020 | 2697 | 0.040 |
Why?
|
| Heartburn | 1 | 2017 | 61 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 856 | 0.040 |
Why?
|
| Methotrexate | 2 | 2020 | 1677 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 8590 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2000 | 901 | 0.040 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 27 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 723 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2003 | 3057 | 0.040 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2016 | 109 | 0.040 |
Why?
|
| Cyclin D2 | 1 | 2016 | 103 | 0.040 |
Why?
|
| Models, Biological | 2 | 2012 | 10102 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2001 | 1036 | 0.040 |
Why?
|
| Benzylamines | 1 | 2017 | 233 | 0.040 |
Why?
|
| Mutation | 2 | 2019 | 28848 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 2092 | 0.040 |
Why?
|
| Viral Vaccines | 1 | 2001 | 567 | 0.040 |
Why?
|
| Quality of Life | 1 | 2016 | 10676 | 0.040 |
Why?
|
| Ikaros Transcription Factor | 1 | 2017 | 208 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 2017 | 279 | 0.040 |
Why?
|
| Phenotype | 3 | 2011 | 16091 | 0.040 |
Why?
|
| Mediastinum | 1 | 2017 | 264 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 7060 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 3983 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 331 | 0.040 |
Why?
|
| Mycosis Fungoides | 1 | 2016 | 150 | 0.040 |
Why?
|
| Protein Binding | 1 | 2008 | 9947 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 9934 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 290 | 0.040 |
Why?
|
| Radioimmunotherapy | 1 | 2015 | 98 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 648 | 0.040 |
Why?
|
| Retreatment | 1 | 2016 | 625 | 0.030 |
Why?
|
| Fatigue | 2 | 2013 | 1385 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2003 | 1379 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 11616 | 0.030 |
Why?
|
| Immunity | 1 | 2000 | 891 | 0.030 |
Why?
|
| Antigens, CD1d | 2 | 2008 | 233 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 10439 | 0.030 |
Why?
|
| Diarrhea | 1 | 2021 | 1339 | 0.030 |
Why?
|
| Acute Disease | 2 | 2017 | 7202 | 0.030 |
Why?
|
| Cohort Studies | 5 | 2019 | 38732 | 0.030 |
Why?
|
| Computational Biology | 2 | 2017 | 3612 | 0.030 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 308 | 0.030 |
Why?
|
| Neutrophils | 2 | 2017 | 3876 | 0.030 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 39737 | 0.030 |
Why?
|
| Pulmonary Heart Disease | 1 | 1993 | 43 | 0.030 |
Why?
|
| Chile | 1 | 2013 | 219 | 0.030 |
Why?
|
| United States | 3 | 2021 | 65579 | 0.030 |
Why?
|
| Carcinoma | 2 | 2002 | 2353 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2011 | 14656 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 832 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2016 | 621 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 386 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 442 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2013 | 288 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2010 | 4040 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 12095 | 0.030 |
Why?
|
| Epoxy Compounds | 1 | 2012 | 146 | 0.030 |
Why?
|
| Israel | 1 | 2013 | 661 | 0.030 |
Why?
|
| Time Factors | 5 | 2017 | 42271 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 2434 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2011 | 123 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 1111 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 20409 | 0.030 |
Why?
|
| Telomerase | 1 | 2016 | 746 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 773 | 0.030 |
Why?
|
| Myeloproliferative Disorders | 1 | 2016 | 513 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 953 | 0.030 |
Why?
|
| Adenine | 1 | 2016 | 894 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2011 | 1617 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 1063 | 0.030 |
Why?
|
| Cell Culture Techniques | 3 | 2004 | 1777 | 0.030 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2009 | 46 | 0.030 |
Why?
|
| Myelopoiesis | 1 | 2010 | 131 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 2578 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2014 | 1062 | 0.020 |
Why?
|
| Observation | 1 | 2011 | 319 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2011 | 291 | 0.020 |
Why?
|
| Paclitaxel | 3 | 2002 | 1652 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 969 | 0.020 |
Why?
|
| Prognosis | 3 | 2018 | 28923 | 0.020 |
Why?
|
| Viral Load | 1 | 2018 | 3216 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2010 | 157 | 0.020 |
Why?
|
| Neutropenia | 1 | 2013 | 852 | 0.020 |
Why?
|
| Biopolymers | 1 | 2009 | 195 | 0.020 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2009 | 211 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 670 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 337 | 0.020 |
Why?
|
| Polyneuropathies | 1 | 2009 | 133 | 0.020 |
Why?
|
| Arsenicals | 1 | 2008 | 127 | 0.020 |
Why?
|
| Piperidines | 1 | 2016 | 1512 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 1127 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2011 | 1700 | 0.020 |
Why?
|
| India | 1 | 2013 | 2196 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2016 | 2475 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 1791 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 936 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 2094 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 4913 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3969 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2017 | 67320 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2009 | 476 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2009 | 633 | 0.020 |
Why?
|
| Graft vs Tumor Effect | 1 | 2006 | 73 | 0.020 |
Why?
|
| ADP Ribose Transferases | 1 | 1986 | 93 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 4129 | 0.020 |
Why?
|
| Oxides | 1 | 2008 | 420 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1993 | 868 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 3713 | 0.020 |
Why?
|
| Exotoxins | 1 | 1986 | 128 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1993 | 887 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 4477 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2014 | 2867 | 0.020 |
Why?
|
| HLA-DR Antigens | 2 | 1999 | 729 | 0.020 |
Why?
|
| Pneumonia | 1 | 2016 | 1942 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 19328 | 0.020 | |